GT199600051A - Metanolsulfonato de (1s, 2s)-1- (4-hidroxifenil)-2-(4-hidroxi-4- fenilpiperidin-1-il)-1-propanol trihidrato. - Google Patents

Metanolsulfonato de (1s, 2s)-1- (4-hidroxifenil)-2-(4-hidroxi-4- fenilpiperidin-1-il)-1-propanol trihidrato.

Info

Publication number
GT199600051A
GT199600051A GT199600051A GT199600051A GT199600051A GT 199600051 A GT199600051 A GT 199600051A GT 199600051 A GT199600051 A GT 199600051A GT 199600051 A GT199600051 A GT 199600051A GT 199600051 A GT199600051 A GT 199600051A
Authority
GT
Guatemala
Prior art keywords
propanol
methanolsulphonate
hydroxiphenyl
phenylpiperidin
trihydrate
Prior art date
Application number
GT199600051A
Other languages
English (en)
Inventor
Marta M Andino
Terry Gene Sinay
Eugene Fred Fiese
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT199600051A publication Critical patent/GT199600051A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

ESTA INVENCION SE REFIERE A LA SAL DE MESILATO DE (1S, 2S)1(4HIDROXIFENIL) 2 (4HIDROXI4FENILPIPERIDIN1IL)1 PROPANOL TRIHIDRATO, A COMPOSICIONES FARMACEUTICAS QUE LA CONTENGAN Y A METODOS PARA SU UTILIZACION EN EL TRATAMIENTO DE ENFERMEDADES DEL SISTEMA NERVIOSO CENTRAL (SNC). ESTOS COMPUESTOS TIENEN LA ESTRUCTURA QUIMICA I, DESCRITA EN EL EXPEDIENTE EN ESTUDIO.
GT199600051A 1995-08-11 1996-07-04 Metanolsulfonato de (1s, 2s)-1- (4-hidroxifenil)-2-(4-hidroxi-4- fenilpiperidin-1-il)-1-propanol trihidrato. GT199600051A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US223895P 1995-08-11 1995-08-11

Publications (1)

Publication Number Publication Date
GT199600051A true GT199600051A (es) 1997-12-26

Family

ID=21699847

Family Applications (1)

Application Number Title Priority Date Filing Date
GT199600051A GT199600051A (es) 1995-08-11 1996-07-04 Metanolsulfonato de (1s, 2s)-1- (4-hidroxifenil)-2-(4-hidroxi-4- fenilpiperidin-1-il)-1-propanol trihidrato.

Country Status (41)

Country Link
US (1) US6008233A (es)
EP (1) EP0843661B1 (es)
JP (1) JP3099072B2 (es)
KR (1) KR100291882B1 (es)
CN (2) CN1615861A (es)
AP (1) AP755A (es)
AR (1) AR004676A1 (es)
AT (1) ATE215072T1 (es)
AU (1) AU710984B2 (es)
BG (1) BG63678B1 (es)
BR (1) BR9610766A (es)
CA (1) CA2228752C (es)
CO (1) CO4750830A1 (es)
CZ (1) CZ296236B6 (es)
DE (1) DE69620191T2 (es)
DK (1) DK0843661T3 (es)
DZ (1) DZ2083A1 (es)
ES (1) ES2170857T3 (es)
GT (1) GT199600051A (es)
HR (1) HRP960372B1 (es)
HU (1) HUP9802862A3 (es)
IL (1) IL122649A (es)
IS (1) IS1945B (es)
MA (1) MA23957A1 (es)
NO (1) NO310458B1 (es)
NZ (1) NZ309134A (es)
OA (1) OA10664A (es)
PE (1) PE4898A1 (es)
PL (1) PL185603B1 (es)
PT (1) PT843661E (es)
RO (1) RO120134B1 (es)
RS (1) RS49521B (es)
RU (1) RU2140910C1 (es)
SA (1) SA96170171B1 (es)
SK (1) SK284209B6 (es)
TN (1) TNSN96104A1 (es)
TR (1) TR199800208T1 (es)
TW (1) TW495502B (es)
UA (1) UA59341C2 (es)
WO (1) WO1997007098A1 (es)
ZA (1) ZA966760B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT777652E (pt) * 1994-08-18 2003-11-28 Pfizer Derivados neuroptotectores de 3-(piperidinil-1)-croman-4.7-diol e de 1-(4-hidrofenil)-2-(piperidinil-1)-alcanol
UA59341C2 (uk) * 1995-08-11 2003-09-15 Пфайзер, Інк. (1s,2s)-1-(4-гідроксифеніл)-2-(4-гідрокси-4-фенілпіперидин-1-іл)-1-пропанолметансульфонат тригідрат
GB9820405D0 (en) * 1998-09-18 1998-11-11 Smithkline Beecham Plc Process
AU3676100A (en) * 1999-04-09 2000-11-14 Mochida Pharmaceutical Co., Ltd. Remedies for neuropathic pain
GB9920917D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel process
GB9920919D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel compound
US6620830B2 (en) * 2000-04-21 2003-09-16 Pfizer, Inc. Thyroid receptor ligands
YU27701A (sh) * 2000-04-28 2003-04-30 Pfizer Products Inc. Postupak za dobijanje trihidrata mezilatne soli 1-(4- hidroksifenil)-2-(4-hidroksi-4-fenilpiperidin-1-il)1-propanola
YU27801A (sh) * 2000-04-28 2003-04-30 Pfizer Products Inc. Postupak za dobijanje trihidrata mezilatne soli 1-(4- hidroksifenil)-2-(4-hidroksi-4-fenilpiperidin-1-il)-1-propanola i korisnih intermedijera
MXPA03001472A (es) 2000-08-16 2003-06-06 Upjohn Co Compuestos para el tratamiento de trastornos adictivos.
EP1186303A3 (en) * 2000-09-06 2003-12-10 Pfizer Products Inc. Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
IL145584A0 (en) 2000-10-02 2002-06-30 Pfizer Prod Inc Nmda nr2b antagonists for treatment
EP1674087A1 (en) 2000-10-02 2006-06-28 Pfizer Products Inc. Prophylactic use of n-methyl-d-aspartate (NMDA) antagonists
UA73619C2 (en) * 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
PL217872B1 (pl) 2001-10-19 2014-08-29 Toyama Chemical Co Ltd Pochodna eteru alkilowego lub jej sól, stanowiąca 1-{3-[2-(1-benzotiofen-5-ylo)etoksy]propylo}-3-azetydynol lub jego sól
KR100517638B1 (ko) 2002-04-08 2005-09-28 주식회사 엘지생명과학 게미플록사신 산염의 새로운 제조방법
EP1942105B8 (en) 2005-10-25 2014-08-13 Shionogi&Co., Ltd. Aminodihydrothiazine derivative
US8653067B2 (en) 2007-04-24 2014-02-18 Shionogi & Co., Ltd. Pharmaceutical composition for treating Alzheimer's disease
KR20100017255A (ko) 2007-04-24 2010-02-16 시오노기 앤드 컴파니, 리미티드 환식기로 치환된 아미노다이하이드로싸이아진 유도체
US8637504B2 (en) 2008-06-13 2014-01-28 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity
EP2360155A4 (en) 2008-10-22 2012-06-20 Shionogi & Co 2-AMINOPYRIDIN-4-ON AND 2-AMINOPYRIDINE DERIVATIVE WITH BACE1-HEMDERING EFFECT
RU2012129168A (ru) 2009-12-11 2014-01-20 Сионоги Энд Ко. Лтд. Производные оксазина
JP5766198B2 (ja) 2010-10-29 2015-08-19 塩野義製薬株式会社 縮合アミノジヒドロピリミジン誘導体
CA2816285A1 (en) 2010-10-29 2012-05-03 Shionogi & Co., Ltd. Naphthyridine derivative
CN103608345A (zh) 2011-04-26 2014-02-26 盐野义制药株式会社 噁嗪衍生物和含有该噁嗪衍生物的bace1抑制剂
WO2014065434A1 (en) 2012-10-24 2014-05-01 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity
ES2723436T3 (es) 2014-09-15 2019-08-27 Rugen Holdings Cayman Ltd Derivados de pirrolopirimidina como antagonistas del receptor NMDA NR2B
US20180271869A1 (en) * 2014-09-22 2018-09-27 Jie Liu Treatment of anxiety disorders and autism spectrum disorders
WO2016126869A1 (en) 2015-02-04 2016-08-11 Rugen Holdings (Cayman) Limited 3,3-difluoro-piperidine derivatives as nr2b nmda receptor antagonists
EP3303323B1 (en) 2015-06-01 2020-01-08 Rugen Holdings (Cayman) Limited 3,3-difluoropiperidine carbamate heterocyclic compounds as nr2b nmda receptor antagonists
EP3544610A1 (en) 2016-11-22 2019-10-02 Rugen Holdings (Cayman) Limited Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK232890A3 (en) * 1989-05-17 1998-11-04 Pfizer 2-piperidino and 2-pyrrolidino-1-alkanols derivatives and preparation method thereof
US5272160A (en) * 1989-05-17 1993-12-21 Pfizer Inc 2-piperidino-1-alkanol derivatives as antiischemic agents
PT777652E (pt) * 1994-08-18 2003-11-28 Pfizer Derivados neuroptotectores de 3-(piperidinil-1)-croman-4.7-diol e de 1-(4-hidrofenil)-2-(piperidinil-1)-alcanol
UA59341C2 (uk) * 1995-08-11 2003-09-15 Пфайзер, Інк. (1s,2s)-1-(4-гідроксифеніл)-2-(4-гідрокси-4-фенілпіперидин-1-іл)-1-пропанолметансульфонат тригідрат

Also Published As

Publication number Publication date
DE69620191D1 (de) 2002-05-02
KR100291882B1 (ko) 2001-10-26
KR19990036321A (ko) 1999-05-25
BG63678B1 (bg) 2002-09-30
CO4750830A1 (es) 1999-03-31
TW495502B (en) 2002-07-21
SK16698A3 (en) 1999-06-11
CZ296236B6 (cs) 2006-02-15
ZA966760B (en) 1998-02-09
TR199800208T1 (es) 1998-05-21
SA96170171B1 (ar) 2006-05-20
RS49521B (sr) 2006-10-27
BG102289A (en) 1998-09-30
UA59341C2 (uk) 2003-09-15
CZ39098A3 (cs) 1999-02-17
DZ2083A1 (fr) 2002-10-23
MA23957A1 (fr) 1997-04-01
CN1198739A (zh) 1998-11-11
CN1615861A (zh) 2005-05-18
JP3099072B2 (ja) 2000-10-16
ATE215072T1 (de) 2002-04-15
NO980574D0 (no) 1998-02-10
NZ309134A (en) 1999-09-29
HUP9802862A2 (hu) 1999-04-28
HRP960372A2 (en) 1998-04-30
IS4643A (is) 1997-12-30
AR004676A1 (es) 1999-03-10
MX9801149A (es) 1998-05-31
DE69620191T2 (de) 2002-07-18
HRP960372B1 (en) 2003-04-30
IL122649A0 (en) 1998-08-16
PL185603B1 (pl) 2003-06-30
RO120134B1 (ro) 2005-09-30
AU5908496A (en) 1997-03-12
IL122649A (en) 2001-08-26
YU46196A (sh) 1999-07-28
CA2228752C (en) 2002-12-10
BR9610766A (pt) 1999-07-13
PL325050A1 (en) 1998-07-06
US6008233A (en) 1999-12-28
TNSN96104A1 (fr) 2005-03-15
NO310458B1 (no) 2001-07-09
PT843661E (pt) 2002-07-31
CA2228752A1 (en) 1997-02-27
NO980574L (no) 1998-02-10
AP9600856A0 (en) 1996-10-31
AU710984B2 (en) 1999-10-07
ES2170857T3 (es) 2002-08-16
JPH10510552A (ja) 1998-10-13
SK284209B6 (en) 2004-11-03
WO1997007098A1 (en) 1997-02-27
RU2140910C1 (ru) 1999-11-10
IS1945B (is) 2004-08-13
EP0843661B1 (en) 2002-03-27
DK0843661T3 (da) 2002-07-22
EP0843661A1 (en) 1998-05-27
HUP9802862A3 (en) 1999-05-28
OA10664A (en) 2000-11-06
AP755A (en) 1999-08-02
PE4898A1 (es) 1998-03-16

Similar Documents

Publication Publication Date Title
GT199600051A (es) Metanolsulfonato de (1s, 2s)-1- (4-hidroxifenil)-2-(4-hidroxi-4- fenilpiperidin-1-il)-1-propanol trihidrato.
GT199700089A (es) Derivados 6.6 o 6.7 -biciclicos sustituidos que contienen pirido o pirimido.
ES2077530B1 (es) Procedimiento para la preparacion de productos farmaceuticos para curar enfermedades tumorales.
GT199800171A (es) Inhibidores selectivos directos o indirectos del factor xa.
GT199700079A (es) Derivados triciclos sustituidos con fenilamino
GT199800063A (es) Carprofeno selectivo para cox-2, para el tratamiento del dolor e inflamacion en perros.
MX9204625A (es) Composicion farmaceutica para el tratamiento de una especie de mamifero, que sufre de deficiencia cardiaca congestiva.
AR012717A1 (es) Trihidrato de la sal de magnesio de s-omeprazol, proceso para su preparacion, composicion farmaceutica, y uso de dicho trihidrato para la fabricacion de medicamentos.
ES2145774T3 (es) Derivados de adenosina que tienen actividad agonista en a2.
BR9808703A (pt) Composição que fornece medicamento solúvel emágua de dissolução relativamente lenta e usosublingual
ES2153076T3 (es) Agentes herbicidas basados en bencisoxazol y bencisotiazol sustituidos.
SE8702642D0 (sv) Lokalt anvendbara, pharmaceutiska beredningar
GT199800205A (es) Compuestos de indol 2,3-sustituidos como agentes anti-inflamatorios y analgesicos.
CO5050328A1 (es) Sistema solvente para la mejor penetracion de compuestos farmaceuticos
ES2167356T3 (es) Utilizacion de tioureilenos y tiabendazol en enfermedades autoinmunitarias e inflamatorias de la piel.
AR046120A1 (es) Fomulaciones fungicidas que contienen cobre
AR011437A1 (es) Composicion farmaceutica para el tratamiento de la migrana y el uso de la misma en la preparacion de un medicamento.
FI880582A (fi) Paperinvalmistuksessa käytettävät uudet valmisteet
NO20031650D0 (no) Nye legemidler for leversykdommer
ATE332140T1 (de) Pharmazeutische zusammensetzungen, welche steroidische strukturen enthalten, und deren verwendungen
MX9306178A (es) Bencimidazoles medicamentos que contienen estos compuestos yprocedimientos para su preparacion.
ES2192608T3 (es) Uso de derivados de alilamina tales como terbinafina, en la fabricacion de un medicamento para el tratamiento de la infeccion por helicobacter pylori de enfermedades asociadas.
ES2190988T3 (es) Agente limpiador y procedimiento para la limpieza de membranas de ultrafiltracion en instalaciones de barnizado electroforetico por inmersion.
MX9302142A (es) Uso de 3r- y 3r,s-difenilmetoxi-1-(3,4-metileno-dioxifenetil)-piperidina y composicion que la contienen.
ES2076518T3 (es) Preparacion dermatologica.